Cancer screening has long been constrained by organ-specific tests that catch disease late. A technology that could simultaneously flag dozens of cancers from a single blood draw — before symptoms emerge — would fundamentally shift oncology from reactive treatment toward proactive interception. That shift is now closer than most clinicians realize, and understanding its current capabilities and honest limitations matters for anyone planning their long-term health strategy.
Methylation-based liquid biopsy works by detecting aberrant DNA methylation patterns on circulating cell-free DNA (cfDNA) shed from tumor cells into the bloodstream. Because these epigenetic signatures appear early in tumorigenesis and are cancer-type-specific, they allow simultaneous detection of multiple malignancies and identification of the tissue of origin from a single sample. This review synthesizes findings from four major clinical programs — CCGA, PATHFINDER, THUNDER, and GUIDE — which collectively demonstrate specificity exceeding 99% and solid tissue-of-origin accuracy. Combining methylation profiling with fragmentomics analysis (the size and fragmentation patterns of cfDNA fragments) meaningfully improves sensitivity for early-stage tumors where circulating tumor DNA shedding is minimal.
The convergence of high-throughput sequencing, digital PCR, and machine learning has driven these performance gains, but this review is a synthesis of existing evidence rather than primary data, which limits its ability to resolve outstanding causal questions. The most significant unresolved issue in the field is clinical utility: high specificity and sensitivity do not yet equal proven mortality reduction. No large-scale, prospectively powered trial has demonstrated that MCED testing lowers cancer-specific death rates — the metric that ultimately justifies population-level screening. Biological confounders, including clonal hematopoiesis and inflammatory conditions that alter cfDNA methylation, remain meaningful sources of false signals. Cost and laboratory standardization are additional barriers to equitable deployment. This review situates methylation liquid biopsy as a genuinely transformative but still maturing technology — confirmatory of the field's trajectory rather than paradigm-shifting on its own. Mortality endpoint trials will be the true test.